What is a DaTscan and should I get one?

What role does DaTscan have in the diagnosis of Parkinson’s disease?

Many patients with Parkinson’s disease (PD) are frustrated and sometimes frankly suspicious about how it is diagnosed. As a neurologist, over the years I’ve heard comments like:

  • “All the doctor did was have me make some movements with my hands and legs and watch me walk and then he told me I had Parkinson’s disease! How is that possible?”
  • “I don’t believe my diagnosis. Aren’t there a bunch of other diseases it could be?”
  • “How can they know for sure? I want a test to prove whether I do or do not have Parkinson’s disease!”

I understand how some patients and care partners can feel this way so I want to address this concern and discuss the role and limitations of a test that is available, known as DaTscan.

PD is a clinical diagnosis

It turns out that the clinical features of PD are unique to PD and often very easy to see via a neurologic exam in a doctor’s office. Rest tremor for example, is seen in virtually no other illness. The skill is being able to distinguish a rest tremor from other tremors, which neurologists are trained to do.

However, some people with PD do not have a rest tremor, which can make the diagnosis trickier. Nevertheless, some elements of the standard in-office neurologic exam are very characteristic, such as

  • decreased blink rate
  • small handwriting, that decreases in size as the writing continues
  • small, movements of the hands and the feet, worse on one side,
  • characteristic stiffness of the arms and the legs, worse on one side,
  • stooped posture
  • decreased arm swing on one side while walking
  • the characteristic walk in which the whole foot is planted flat at one time – instead of the heel being planted on the ground first
  • the characteristic way of turning by taking multiple steps and not pivoting

If there are enough of these features present during an exam, with or without a rest tremor, especially if coupled with a history of certain non-motor symptoms that typically appear before the movement symptoms of PD, such as constipation, loss of smell and REM behavior sleep disorder, the practitioner will feel sure of the diagnosis.

It may seem like a brief exam, but all of the above can be assessed quickly. It is important to note, that a person who displays some of these features on exam may be unaware of them, while a trained neurologist can easily identify them. The converse is also true – a person may be very concerned that his/her symptoms are consistent with PD, while a trained neurologist can easily reassure the person that that is not the case.

DaTscan: A test to help in the diagnosis of PD

In 2011, the Food and Drug Administration (FDA) approved an imaging test to help diagnose PD. In this test, a radioactive tracer, Ioflupane 123I, also known as DaTscan, is injected into the blood, where it circulates around the body and makes its way into the brain. It attaches itself to the dopamine transporter, a molecule found on dopamine neurons. Several hours after the tracer has been injected, special imaging equipment scans the head to detect the presence of DaTscan.

People with PD will typically have a smaller signal in a part of the brain called the striatum, where the ends of the dopamine neurons are meant to be. Here is a normal scan on the left, which would indicate a healthy dopamine system, next to an abnormal scan on the right, which would indicate an unhealthy dopamine system.

It is important to note that conventional MRI imaging will appear normal in PD and is therefore not helpful in confirming the diagnosis. Other atypical parkinsonian conditions, such as vascular parkinsonism however, can have abnormalities on MRI, so the test may be done to rule out other diagnoses.

Diagnosis of PD via DaTscan and clinical exam are similarly accurate

Despite the DaTscan being available to help diagnose PD, in most clinical situations, a DaTscan will not add information to what can be gleaned from the clinical exam. One study actually demonstrated that the accuracy of diagnosis in early PD was the same whether the diagnosis was reached using clinical exam or using DaTscan.

Pitfalls of DaTscan

DaTscan will appear abnormal in any disease in which there is a loss of dopamine nerve endings in the striatum. Therefore, Parkinson-plus syndromes, discussed in a prior blog, such as Progressive supranuclear palsy (PSP), Corticobasal ganglionic degeneration (CBGD) and Multiple system atrophy (MSA) all typically demonstrate abnormal DaTscans. DaTscan therefore cannot be used to distinguish between these syndromes.

Every medical test (for any disease) has a false positive and a false negative rate. This means, that it is inevitable that in a certain (small) percentage of people who have PD, the DaTscan will be read as normal and in a certain (small) percentage of people without PD, the DaTscan will be read as abnormal. Results of any medical test that is performed, must therefore be considered within the entire clinical context.

When is DaTscan helpful?

There are situations in which DaTscan can be very helpful in securing a diagnosis – when neurologic exam findings are not clear-cut. Although DaTscan cannot distinguish PSP, CBGD, and MSA from PD, studies suggest that it may be able to distinguish drug-induced parkinsonism and vascular parkinsonism from PD.

The FDA indication for DaTscan is for distinguishing between PD and essential tremor (ET). Usually it is quite straightforward for a neurologist to distinguish between the tremors of ET and the tremors of PD.  PD tremors occur at rest and are accompanied by slowness and stiffness of the limb, whereas ET tremors occur with action and are not accompanied by slowness and stiffness of the limb. However, some people may have mixed tremor features making the diagnosis more difficult. In those cases, a DaTscan can be very useful.

Limitations of the test

Currently, DaTscan that is in clinical use is not quantitative, which means that the test is not designed to determine how impaired the dopamine system is – just whether it is or not. This means that the test will not tell you whether the disease has progressed over time and is not used to follow a patient’s disease. It also can’t determine whether there has been improvement in the dopamine system, in the context of a person taking an experimental medication in a clinical trial, for example. It also is not used currently as a clinical test to screen for the disease before motor symptoms are evident. Because of these limitations, the search continues for additional measurable indicators, known as biomarkers, to help diagnosis and manage PD.

Tips and Takeaways

  • DaTscan is a test that can help in the diagnosis of PD, although in most situations a clinical exam done by a neurologist offers the same information.
  • Neurologists are skilled to diagnose PD through a clinical exam. While the exam to some may seem very basic and thus a PD diagnosis subjective or questionable, neurologists are well-trained to assess and diagnose (in most cases) with confidence.
  • DaTscan may be useful in distinguishing PD from certain conditions, but not from others, so talk with your neurologist about whether DaTscan would be useful in your specific situation.
  • DaTscan is not a test used for monitoring PD progression. It can be used to help clarify a PD diagnosis, but it is not a test you would undergo multiple times during the course of your disease.

 

Share this page:

Do you have a question or issue that you would like Dr. Gilbert to explore? Suggest a Topic

Dr. Rebecca Gilbert

APDA Vice President and Chief Scientific Officer

Dr. Gilbert received her MD degree at Weill Medical College of Cornell University in New York and her PhD in Cell Biology and Genetics at the Weill Graduate School of Medical Sciences. She then pursued Neurology Residency training as well as Movement Disorders Fellowship training at Columbia Presbyterian Medical Center. Prior to coming to APDA, she was an Associate Professor of Neurology at NYU Langone Medical Center. In this role, she saw movement disorder patients, initiated and directed the NYU Movement Disorders Fellowship, participated in clinical trials and other research initiatives for PD and lectured widely on the disease.

A Closer Look ArticlePosted in News

DISCLAIMER: Any medical information disseminated via this blog is solely for the purpose of providing information to the audience, and is not intended as medical advice. Our healthcare professionals cannot recommend treatment or make diagnoses, but can respond to general questions. We encourage you to direct any specific questions to your personal healthcare providers.